Community/Retail

Research highlights the link between earlier menopause, cardiac function, and brain health, emphasizing the need for sex-specific dementia risk strategies.

Research highlights the impact of provider type on menopause treatment, revealing a need for standardized education to improve care quality for women.

Language preference significantly impacts access to continuous glucose monitors for type 2 diabetes, revealing critical disparities in diabetes care.

Elinzanetant, the first FDA-approved nonhormonal treatment for menopause-related hot flashes, offers women a new, effective relief option.

Explore the promising data on elinzanetant for managing menopause-related vasomotor symptoms, highlighting its tolerability and minimal side effects.

A heightened ratio of non-high-density lipoprotein cholesterol (non-HDL-C) to HDL-C was associated with depression, with risk mediated by body mass index.

The authors wrote that their findings show a necessary update following early data from the Women’s Health Initiative.

Further research is needed to better understand which characteristics may better predict who are more likely to benefit from estrogen-based menopausal hormonal therapy (MHT) for anxiety.

Samantha Picking, PharmD, highlights pharmacists’ leadership in immunization initiatives, public health collaborations, and the evolving role of community pharmacy in preventive care.

If approved, SYD-101 would have been the first FDA-approved treatment for pediatric myopia, offering hope to millions of affected children in the US.

Megan Dulohery Scrodin, MD, highlights Mayo Clinic's innovative COPD care model, emphasizing multidisciplinary collaboration and AI tools for improved patient outcomes.

Experts discuss breakthroughs in respiratory virus vaccines.

Elinzanetant shows promise as a new treatment for menopause-related vasomotor symptoms, offering rapid relief and a favorable safety profile.

New clinical trial results suggest G-CSF as a promising alternative for managing hot flashes in menopausal women, without the risks of traditional therapies.

Research highlights the impact of sleep disturbances and vasomotor symptoms (VMS) on HRQoL in women transitioning to menopausal period, emphasizing the need for effective management.

Embedding standards in pharmacy practice help ensure medication quality, safety, and patient understanding.

Research reveals varying impacts of GLP-1 receptor agonists on asthma risk, urging careful medication selection for patients with diabetes and respiratory issues.

Explore how pharmacists can better support indigenous and Hispanic women during menopause through culturally sensitive care and family involvement.

When treating vasomotor symptoms (VMS), 15- and 20-mg doses of estetrol (E4) did not significantly hinder postmenopausal women’s blood pressure, including those with cardiovascular risks.

Chronic graft-vs-host disease (cGVHD) is the leading cause of late, non-relapse mortality for patients who have undergone an allogeneic hematopoietic stem cell transplant. Axatilimab, which has durable responses and an attractive safety profile, offers a novel mechanism of action for the treatment for patients who have not succeeded with at least 2 prior lines of systemic therapy.

A digital therapeutic app enhances access to behavioral cough suppression therapy.

Community pharmacists are especially valuable amid lower interest and staff shortages.

Infectious disease experts provide the latest updates in RSV, pneumococcal disease, whooping cough, and multidrug-resistant tuberculosis.

New research reveals how menopausal hormone therapy impacts cognitive health in postmenopausal women, highlighting the importance of administration routes and estrogen types.

Overdoses remain alarmingly high despite new tools like OTC Naloxone, highlighting persistent barriers to care.

Experts outline innovative approaches to reduce inequities in diagnostic access and optimize patient outcomes.